Why Reshoring Is An Essential Strategy For ADC Supply Chain Security

By Matt Dodge and Ross Bemowski, MilliporeSigma

Currently, the overarching drivers for reshoring to Western nations are the United States’ BIOSECURE Act and a combination of trade and political instability. While these dynamics may be temporary, an enduring focus will remain on geographically strategic supply chains that decrease complexity and favor local supply chains.

Reshoring challenges are amplified when transitioning the supply chain for complex programs like antibody-drug conjugates (ADCs), wherein raw materials, linker/payload, and bioconjugation all must be sourced. Therefore, it is critical to understand the long-term impacts of how the reshoring process is executed and how the right CDMO can help facilitate a smoother transition and a more robust supply chain moving forward.

Technical teams, MSAT, quality personnel, and regulatory experts are all deeply interconnected in GMP production. Leveraging a single CDMO that operates an integrated supply chain ensures these teams are engaged early, aligned on the drug developer’s procedures, and able to collaboratively identify opportunities for optimization or potential scale-up issues. Working closely from the start also enables CDMO teams to map out activities that can be conducted in parallel, accelerating the transition process as well as sourcing and production that will occur afterward.